OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]openaire.eu

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Bourdin, Claire
Languages: English
Types: Doctoral thesis
Subjects: QR180, RM, QR355
Hepatitis C virus is an infectious disease affecting millions of people worldwide and causing chronic liver disease. The current standard of care is not only long but causes numerous side effects. Due to incomplete virological response and poor tolerability, only 50% of the patients are cured, with variability by genotype. Despite the\ud development of non-enzymatic viral protein inhibitors, new therapies target mainly enzymes responsible for viral replication or translation. Being commonly used for\ud antiviral and anticancer therapy, nucleosides analogues have played an important role as anti-HCV agents.\ud Despite their potency and selectivity, nucleoside analogues appear to be poor substrates for metabolic enzymes. In particular, the first essential phosphorylation step is often rate-limiting thus, resulting in poor bioactivation to the active triphosphate form. Hence, monophosphate prodrug strategies have been applied to efficiently deliver\ud intracellularly the key monophosphate derivatives. Such strategies have been successfully used for anti-HCV therapy and the phosphoramidate ProTide INX-08189, discovered in our lab, is one such example.\ud Aiming at developing back-up molecules of INX-08189, we report in the present work, the synthetic strategies to obtain several modified β-2’-C-methyl-6-O-methyl guanosine\ud and other modified β-2’-C-methyl purine nucleoside analogues. The phosphoramidate ProTide approach and the phosphorodiamidate approach were applied to these modified\ud nucleosides. In-vitro, and sometimes in-vivo evaluation against HCV replication is reported, and the mechanism of bioactivation to their corresponding monophosphate\ud species is discussed. Enzymatic experiments using carboxypeptidase Y and Huh-7 cell lysates were carried out to investigate the release of the monophosphate forms. We also investigated the hydrolysis of the 6-O-methyl group at the nucleoside level with adenosine deaminase enzyme, and at the monophosphate level using molecular docking\ud in adenosine deaminase like protein-1. Eventually, the intracellular putative mechanism of activation of the ProTides was studied using molecular modeling with cathepsin A enzyme and human Hint-1 phosphoramidase.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • (19) Erion, M. D.; Van Poelje, P. D.; Dang, Q.; Kasibhatla, S. R.; Potter, S. C.; Reddy, M. R.; Reddy, K. R.; Jiang, T.; Lipscomb, W. N.
    • MB06322 (CS-917): a potent and selective inhibitor of fructose 1,6- bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
    • Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 7970−7975; J. Hepatol. 2011, 54 (1), S187.
    • (20) Nillroth, U.; Besidsky, Y.; Classon, B.; Chattopadhyaya, J.; Ugi, I.; Danielson, U. H. Specific interaction between HIV-1 proteinase and 5′-phosphate peptidomimetic derivatives of nucleoside analogs. Drug Des. Discovery 1995, 13 (1), 43−54.
    • (21) Nillroth, U.; Vrang, L.; Ahlsen, G.; Besidsky, Y.; Chattopadhyaya, J.; Ugi, I.; Danielson, U. H. The use of 5′- phosphate derivatives of nucleoside analogs as inhibitors of HIV-1 replication. Antiviral Chem. Chemother. 1995, 6 (1), 50−64.
    • (22) Romanowska, K. Biological activity and topological properties of HIV-1 inhibitors. Pol. J. Chem. 1993, 67 (4), 755−757.
    • (23) Barry, A.; Patti, J.; Matson, M.; Boehlecke, B.; Wenzel, E.; Pentikis, H.; Alam, J.; Henson, G. A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 Nucleotide Polymerase Inhibitor, in Healthy Subjects. 46th European Association for the Study of the Liver, Berlin, Germany, March 30− April 3, 2011.
    • (24) McGuigan, C.; Madela, K.; Aljarah, M.; Gilles, A.; Battina, S. K.; Ramamurty, C. V. S.; Srinivas Rao, C.; Vernachio, J.; Hutchins, J.; Hal, A.; Kolykhalov, A.; Henson, G.; Chamberlain, S. Dual prodrugs of 2′- C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus. Biomed. Chem. Lett. 2011, 21, 6007−6012.
    • (25) McGuigan, C.; Salgado, A.; Yarnold, C.; Harries, T. Y.; De Clercq, E.; Balzarini, J. Novel nucleoside phosphoramidates as inhibitors of HIV: studies on the stereochemical requirements of the phosphoramidate amino acid. Antivir. Chem. Chemother. 1996, 7, 184− 188.
    • (26) McGuigan, C.; Tsang, H.-W.; Cahard, D.; Turner, K.; Velazquez, S.; Salgado, A.; Bidois, L.; Naesens, L.; De Clercq, E.; Balzarini, J. Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation. Antiviral Res. 1997, 35, 195−204.
    • (27) McGuigan, C.; Tsang, H.-W.; Sutton, P. W.; De Clercq, E.; Balzarini, J. Synthesis and anti-HIV activity of some novel chain extended phosphoramidate derivatives d4T (stavudine) esterase hydrolysis as a rapid predictive test for antiviral potency. Antivir.
    • Chem. Chemother. 1998, 9, 109−115.
    • (28) McGuigan, C.; Gilles, A.; Madela, K.; Aljarah, M.; Holl, S.; Jones, S.; Vernachio, J.; Hutchins, J.; Ames, B.; Bryant, D.; Gorovits, E.; Ganguly, B.; Hunley, D.; Hall, A.; Kolykhalov, A.; Liu, Y.; Muhammad, J.; Raja, Walters, N.; Wang, J.; Chamberlain, S.; Henson, G. Phosphoramidate ProTides of 2′-C-Methylguanosine as Highly Potent Inhibitors of Hepatitis C virus. Study of Their in Vitro and in Vivo Properties. J. Med. Chem. 2010, 53, 4949−4957.
    • (29) McGuigan, C.; Sutton, P. W.; Cahard, D.; Turner, K.; O'Leary, G.; Wang, Y.; Gumbleton, M.; De Clercq, E.; Balzarini, J. Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T). Antivir. Chem. Chemother 1998, 9, 473−479.
    • (30) Derudas, M.; Carta, D.; Brancale, A.; Vanpouille, C.; Lisco, A.; Margolis, L.; Balzarini, J.; McGuigan, C. The Application of Phosphoramidate Protide Technology to Acyclovir Confers AntiHIV Inhibition. J. Med. Chem. 2009, 52, 5520−5530.
    • (31) Endrizzi, J. A.; Breddam, K.; Remington, S. J. 2.8-A structure of yeast serine carboxypeptidase. Biochemistry 1994, 33, 11106−11120.
    • (32) Vernachio, J. H.; Bleiman, B.; Bryant, K. D.; Chamberlain, S.; Hunley, D.; Hutchins, J.; Ames, B.; Gorovits, E.; Ganguly, B.; Hall, A.; Kolykhalov, A.; Liu, Y.; Muhammad, J.; Raja, N.; Walters, R. C.; Wang, J.; Williams, K.; Patti, J. M.; Henson, G.; Madela, K.; Aljarah, M.; Gilles, A.; McGuigan, C. INX-08189, a Phosphoramidate Prodrug of 6- O-Methyl-2′-C-Methyl Guanosine, is a Potent Inhibitor of Hepatitis C V i r u s R e p l i c a t i o n w i t h E x c e l l e n t P h a r m a c o k i n e t i c a n d Pharmacodynamic Properties. Antimicrob. Agents Chemother. 2011, 55, 1843−1851.
  • No related research data.
  • No similar publications.
  • BioEntity Site Name
    1kpfProtein Data Bank
    1yscProtein Data Bank

Share - Bookmark

Cite this article

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok